1. To discuss the increasing applicability of transcriptomic data in the clinical oncology setting
2. To demonstrate how gene expression can be leveraged to validate and explore population-specific molecular mechanisms of cancer etiology.
3. To demonstrate how germline risk variants and tumor transcriptomes from breast cancer patients may be used to build prognostication models with broader applicability across breast cancer patients.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation